Insider transactions

EDGAR

Daxor Corporation

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
6 transactions, 28,941 shares
Sum of shares × price per share: 18,970 4 without a price are not valued.
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–14 of 14

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-28 Filed 2026-09-01Jefferies John Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Daxor Common Stock
Acquired (A)2,4510—26,008Direct (D) No
F1
  • F1 2,451 shares granted vest on August 28, 2026.
Open filing 0001493152-26-040999 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25DesRosiers Caleb Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock options (right to buy) — underlying Common Stock (2,500) — exercise price 10.14
Acquired (A)2,5000—2,500Direct (D) No
F1, F2
  • F1 Stock options granted on June 23, 2026 are contingent on the approval of the Securities Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan (the Plan)
  • F2 The stock options will vest in three (3) installments - June 23, 2026 (833); June 23, 2027 (833); June 23, 2028 (834)
Open filing 0001493152-26-030165 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Goudie Joy S. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (right to buy) — underlying COMMON STOCK (2,500) — exercise price 10.14
Acquired (A)2,5000—2,500Direct (D) No
F1, F2
  • F1 Stock options granted on June 23, 2026 are contingent on the approval of the Securities Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan (the Plan).
  • F2 The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)
Open filing 0001493152-26-030180 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Cremisi Henry D. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (right to buy) — underlying COMMON STOCK (2,500) — exercise price 10.14
Acquired (A)2,5000—2,500Direct (D) No
F1, F2
  • F1 Stock options granted on June 23, 2026 are contingent on the approval of the Securities Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan (the Plan).
  • F2 The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)
Open filing 0001493152-26-030175 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Feldschuh Michael Richard Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Daxor Common Stock
Acquired (A)30,0000—243,694Direct (D) No
F1
  • F1 30,000 shares granted vest on June 23, 2026
Open filing 0001493152-26-030192 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Feldschuh Jonathan Adam Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Daxor Common Stock
Acquired (A)25,0000—78,908Direct (D) No
F1
  • F1 25,000 shares granted vest on June 23, 2026.
Open filing 0001493152-26-030187 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Feuer Edward Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (right to buy) — underlying COMMON STOCK (2,500) — exercise price 10.14
Acquired (A)2,5000—2,500Direct (D) No
F1, F2
  • F1 Stock options granted on June 23, 2026 are contingent on the approval of the Securities Exchange Commission (SEC) to amend the Daxor Corporation 2020 Incentive Compensation Plan (the Plan).
  • F2 The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)
Open filing 0001493152-26-030171 Read from the filing’s XML Dispute this row
2026-06-23 Filed 2026-06-25Michel Robert J Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Daxor Common Stock
Acquired (A)12,0000—33,050Direct (D) No
F1
  • F1 12,000 shares granted vest on June 23, 2026.
Open filing 0001493152-26-030197 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-10Feldschuh Michael Richard Director · Officer: Chief Executive Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)1,0009.07
9,070

Derived: shares × price per share. Exact value 9070.00.

213,694Direct (D) No— Open filing 0001493152-26-016105 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-03-31Michel Robert J Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)1,0009.90
9,900

Derived: shares × price per share. Exact value 9900.00.

21,050Direct (D) No— Open filing 0001493152-26-014397 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Jefferies John Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)3,6560—21,272Direct (D) No
F1
  • F1 3,656 shares granted vest on March 20, 2029.
Open filing 0001493152-26-012444 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Jefferies John Officer: Chief Medical Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)2,2850—23,557Direct (D) No
F2
  • F2 2,285 shares granted vested on March 20, 2026
Open filing 0001493152-26-012444 Read from the filing’s XML Dispute this row
2025-12-09 Filed 2025-12-11Michel Robert J Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)3,0000—20,050Direct (D) No
F1
  • F1 3,000 shares granted vest on December 9, 2025.
Open filing 0001493152-25-027230 Read from the filing’s XML Dispute this row
2025-12-09 Filed 2025-12-11Feldschuh Jonathan Adam Director · Officer: Chief Scientific Officer
P

Open market or private purchase of non-derivative or derivative security

Daxor Common Stock
Acquired (A)18,0000—53,908Direct (D) No
F1
  • F1 18,000 shares granted vest on December 9, 2025.
Open filing 0001493152-25-027228 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–15 of 15

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
THOMPSON SIEGEL WALMSLEY LLC Partly reported under another manager241,767 SH2,720 dollarsUnchanged Prior quarter: 241,767Open filing 0001008322-26-000012 Filed 2026-11-05 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 49,108 SH545,099 dollarsHigher by 277 Prior quarter: 48,831Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
BFC Planning, Inc. 33,700 SH379,125 dollarsLower by 3,000 Prior quarter: 36,700Open filing 0001420506-26-002645 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager29,521 SH332,111 dollarsHigher by 100 Prior quarter: 29,421Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
HRT FINANCIAL LP 15,452 SH171 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
NANO CAP NEW MILLENNIUM GROWTH FUND L P Partly reported under another manager15,000 SH168,750 dollarsHigher by 2,500 Prior quarter: 12,500Open filing 0001277890-26-000005 Filed 2026-11-13 Dispute this row
Crescent Grove Advisors, LLC 12,423 SH139,759 dollarsUnchanged Prior quarter: 12,423Open filing 0000892712-26-000371 Filed 2026-10-21 Dispute this row
SBI Securities Co., Ltd. 3,131 SH35,224 dollarsUnchanged Prior quarter: 3,131Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
MORGAN STANLEY Partly reported under another manager3,087 SH34,729 dollarsUnchanged Prior quarter: 3,087Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 1,037 SH11,511 dollarsUnchanged Prior quarter: 1,037Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager600 SH7,020 dollarsHigher by 100 Prior quarter: 500Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Godfrey Financial Associates, Inc. 100 SH1,125 dollarsNot in the prior quarter’s filings read Open filing 0002097943-26-000004 Filed 2026-11-10 Dispute this row
UBS Group AG Partly reported under another manager94 SH1,058 dollarsLower by 78 Prior quarter: 172Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager41 SH480 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager4 SH47 dollarsLower by 2 Prior quarter: 6Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Aristides Capital LLC 41,689 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 27,131 SH
  • BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 6,000 SH
  • Tower Research Capital LLC (TRC) 305 SH
  • WELLS FARGO COMPANY/MN 0 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

No Schedule 13D or 13G naming this issuer is in the store; this is not a statement that none were filed.

What was read

2,128,558 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202251,728
2023199,811
2024209,823
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to Daxor Corporation